Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06414148 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

Study acronym: EpLCART
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 37 wordsv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 7, 2024 to May 14, 2024
    • Site details revised at 6 of 6 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase II open-label, two-arm randomised non-comparative, multi-centre study to evaluate the efficacy of Epcor-only (Epcoritamab alone) or Epcor-R2 (Epcoritamab, lenalidomide and rituximab) as consolidation post anti-CD19 CAR T-cell therapy for patients that have responded by conventional criteria but who are at high risk of progression by virtue of being Minimal Residual Disease (MRD) positive as determined by a Circulating Tumour DNA (ctDNA) assay.
Trial Details
NCT Number NCT06414148
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Collaborators: AbbVie
Conditions
(from sponsor)		 Relapsed/Refractory Large B-cell Lymphoma
Related terms Lymphoma, Neoplasm, Residual, Recurrence
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov